Abstract: Prescribed herein are novel non-steroidal ligands for the estrogen receptor which possess tissue-dependent estrogenic and antiestrogenic activity as well as methods for making the same and their applications in treating a variety of disease states.
Abstract: The present invention relates to a process for the preparation of finasteride, the compound of formula (I), comprising the reaction of the compound of formula (II) with t-butylamine.
Abstract: The present invention relates to peptides which show improved Neuropeptide Y antagonism to pharmaceutical compositions containing such peptides and their use.
Type:
Grant
Filed:
February 17, 1995
Date of Patent:
September 23, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Alejandro Jose Daniels, Dennis Heyer, Antonio Landavazo, Johann Jakob Leban, Andreas Spaltenstein
Abstract: In combination an automated blend waste reclaim apparatus and a pharmaceutical tablet compression machine to facilitate reintroduction of blend into the tablet compression machine and comprising a filter operatively connected to the bulk material container of the tablet compression machine which serves to collect excess blend being pneumatically removed from the tablet compression machine. A blast of compressed air serves to periodically remove blend from the filter, and the blend is then caused to be reintroduced into the bulk material container of the pharmaceutical tablet compression machine.
Abstract: Novel pyrrolidine compounds which are useful for inhibiting the function of Type IV phosphodiesterase (PDE-IV) as well as methods for making the same are disclosed. Applications in treating inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, are also disclosed.
Type:
Grant
Filed:
September 20, 1993
Date of Patent:
September 9, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Paul Lawrence Feldman, Jeffrey Alan Stafford
Abstract: A computer based pharmaceutical care cognitive services management system and method allows the transformation of a pharmacist from a vendor to a health care provider. The pharmaceutical care cognitive services management system and method captures all of the value added by a pharmacist to a patient encounter by permitting multiple RARs (Reasons, Actions, Results) to be associated with a single SOAP (Subjective, Objective, Assessment, Plan). This system enables the pharmacist to financially recover for each analytical or counseling session and/or service provided to the user associated with a single transaction. The pharmaceutical care cognitive services management system and method also enables the efficient processing of interruptions to cognitive and counseling sessions.
Type:
Grant
Filed:
January 17, 1995
Date of Patent:
September 9, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Keith Daniel Rhodes, Kenneth Wayne Dunn, Samir Ibrahim Abed, Donald Collins Mullen, Jr., Jon Martin Schwartz
Abstract: The present invention relates to benzoquinazoline thymidylate synthase inhibitors, processes for preparing them and pharmaceutical formulations containing them.
Type:
Grant
Filed:
May 25, 1995
Date of Patent:
September 2, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
William Pendergast, Scott Howard Dickerson
Abstract: The present invention is directed to the following compounds of formula (I): ##STR1## wherein l is an integer of from 0 to 4; m is an integer of from 0 to 5; n is an integer of from 0 to 2; R and R' are atoms or groups independently selected from halogen, nitro, phenylalkoxy, C.sub.1-4 alkoxy, C.sub.1-6 alkyl and --O(CH.sub.2).sub.p SO.sub.3 R" wherein p is an integer of from 1 to 4 and R" is hydrogen or C.sub.1-6 alkyl, wherein said phenylalkoxy, alkoxy and alkyl groups are optionally substituted by one or more halogen atoms; R.sup.4 is a C.sub.1-6 straight alkyl group; and R.sup.5 is a C.sub.2-6 straight alkyl group; and their salts, solvates and physiologically functional derivatives, with processes and novel intermediates for their preparation, with pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidaemic conditions, such as atherosclerosis.
Abstract: A water-dispersible tablet comprises acyclovir and a dispersing agent. The dispersing agent is a swellable clay such as a smectite, e.g. Veegum F or bentonite, and is generally present within the granules of the tablet to provide a tablet which is capable of dispersing in water within 3 minutes to provide a dispersion which will pass through a 710 .mu.m sieve. The tablet can be optionally film-coated in which case the dispersion time is less than 5 minutes.
Abstract: The present invention relates to bezoquinazoline thymidylate synthase inhibitors, to pharmaceutical formulations containing them and to their use in medicine.
Type:
Grant
Filed:
May 26, 1995
Date of Patent:
August 26, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
William Pendergast, Scott Howard Dickerson
Abstract: A method of treating anxiety is disclosed comprising administering 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine or a pharmaceutically acceptable acid addition salt thereof.
Abstract: A method for the treatment of depression in a human being, the method comprising administering to the human being an antidepressant effective amount of a compound of the following formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R and R.sup.1 are independently hydrogen or fluorine.
Type:
Grant
Filed:
May 19, 1995
Date of Patent:
July 15, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Nariman Bomanshaw Mehta, Grady Evan Boswell, James Leroy Kelley
Abstract: A medicament carrier for use in a dry powder inhalator device wherein the medicament carrier has at least one carrier screen portion. The carrier screen portion defines a plurality of interstices therein and carries a powdered medicament which is loaded onto the carrier screen portion surface such that the interstices of the carrier screen portion at least partially open and free of the dry powdered medicament.
Abstract: This invention pertains to novel benzodiazepine compounds of formula (I) ##STR1## which exhibit agonistic activity for CCK-A receptors, enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals for use in medicine as anorectic agents in the regulation of appetite, the treatment of obesity and the maintenance of weight loss.
Type:
Grant
Filed:
October 13, 1995
Date of Patent:
July 8, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Elizabeth Ellen Sugg, Christopher Joseph Aquino, Jerzy Ryszard Szewczyk, Harry Finch, Robin Arthur Ellis Carr
Abstract: Treatment of animals or humans carrying or infected with HTLV-I, HTLV-I (including HTLV-I-associated leukemias or lymphomas), non-A, non-B hepatitis virus, hepatitis B virus, EBV, equine infectious anaemia or other lentiviruses or having antibodies to said viruses is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Type:
Grant
Filed:
February 26, 1993
Date of Patent:
July 1, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
Abstract: Pharmaceutical compositions containing 5-substituted uracil compounds are disclosed. The compositions are preferably in the form of a tablet or capsule.
Type:
Grant
Filed:
November 9, 1994
Date of Patent:
July 1, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Thomas Spector, David J. T. Porter, Saad George Rahim
Abstract: The present invention relates to certain purine nucleoside analogues containing a carbocyclic ring in place of the sugar residue, salts, esters and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and to the use of such compounds in therapy, particularly the treatment or prophylaxis of certain vital infections.
Type:
Grant
Filed:
September 12, 1994
Date of Patent:
June 24, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Susan Mary Daluge, Douglas Alan Livingston
Abstract: Compounds or formula (I), wherein R.sup.1 represents an n-propoxy, cyclobutoxy, cyclopropylamino, piperidino or pyrrolidino group; or a physiologically functional derivative thereof. The invention further includes methods for the preparation of compounds of formula (I), compositions containing them and the use of these compounds as antiviral agents.
Type:
Grant
Filed:
October 5, 1994
Date of Patent:
June 10, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Charlene L. Burns, George W. Koszalka, Thomas A. Krenitsky, Susan M. Daluge
Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
June 3, 1997
Assignee:
Glaxo Wellcome Inc.
Inventors:
Alistair A. Miller, Malcolm S. Nobbs, Richard M. Hyde, Michael J. Leach